Oral Lipid Nanocrystal Amphotericin B for Cryptococcal Meningitis: A Randomized Clinical Trial
Top Cited Papers
Open Access
- 22 August 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 77 (12) , 1659-1667
Abstract
Amphotericin B is the gold standard treatment for severe mycoses. A new orally delivered, less-toxic formulation of amphotericin has been developed. In our randomized clinical trial, we tested oral lipid nanocrystal (LNC) amphotericin B (MAT2203, Matinas Biopharma) vs intravenous (IV) amphotericin for human immunodeficiency virus–associated cryptococcal meningitis in 4 sequential cohorts. Two pilot cohorts assessed safety and tolerability (n = 10 each), and 2 cohorts assessed efficacy with/without 2 IV loading doses (n = 40 each). The experimental arm received 1.8 g/d oral LNC amphotericin through 2 weeks with 100 mg/kg/d flucytosine, then 1.2 g/d LNC amphotericin through 6 weeks. The randomized control arm (n = 41) received 7 days of IV amphotericin with flucytosine, then 7 days of fluconazole 1200 mg/d. The primary end point was cerebrospinal fluid (CSF) early fungicidal activity (EFA). We randomized 80 participants to oral LNC amphotericin + flucytosine with (n = 40) and without (n = 40) 2 IV loading doses and 41 control participants to IV amphotericin + flucytosine. Mean EFA was 0.40 log10 colony-forming units (CFU)/mL/d for all-oral LNC amphotericin, 0.42 log10 Cryptococcus CFU/mL/d for oral LNC amphotericin with IV loading doses, and 0.46 log10 CFU/mL/d for IV amphotericin controls. LNC amphotericin groups achieved 2-week CSF sterility in 63% (44 of 70) vs 68% (23 of 34) of controls. The 18-week survival was 85% (34 of 40) with all-oral LNC amphotericin, 90% (36 of 40) with oral LNC amphotericin given IV loading doses, and 85% (35 of 41) with IV amphotericin. Grade 3–4 laboratory adverse events occurred less frequently in LNC amphotericin groups (41%) than the IV amphotericin group (61%, P = .05), particularly for anemia (21% vs 44%; P = .01) and potassium (5% vs 17%; P = .04). This new oral amphotericin B LNC formulation appears promising for cryptococcal meningitis with antifungal activity, similar survival, and less toxicity than IV amphotericin. NCT04031833.Keywords
Funding Information
- NIH (R01NS086312))
- Matinas BioPharma (AI001123, AI001124))
This publication has 28 references indexed in Scilit:
- Standardized Electrolyte Supplementation and Fluid Management Improves Survival During Amphotericin Therapy for Cryptococcal Meningitis in Resource-Limited SettingsOpen Forum Infectious Diseases, 2014
- Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal MeningitisNew England Journal of Medicine, 2014
- Nosocomial Drug-Resistant Bacteremia in 2 Cohorts with Cryptococcal Meningitis, AfricaEmerging Infectious Diseases, 2014
- Multisite Validation of Cryptococcal Antigen Lateral Flow Assay and Quantification by Laser Thermal ContrastEmerging Infectious Diseases, 2014
- Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV‐Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 PatientsClinical Infectious Diseases, 2009
- IL-4/IL-13-Dependent Alternative Activation of Macrophages but Not Microglial Cells Is Associated with Uncontrolled Cerebral CryptococcosisThe American Journal of Pathology, 2009
- High‐Dose Amphotericin B with Flucytosine for the Treatment of Cryptococcal Meningitis in HIV‐Infected Patients: A Randomized TrialClinical Infectious Diseases, 2008
- Outcomes of Cryptococcal Meningitis in Uganda Before and After the Availability of Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2008
- Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trialThe Lancet, 2004
- Treatment of Experimental Cryptococcal Meningitis with Amphotericin B, 5-Fluorocytosine, and KetoconazoleThe Journal of Infectious Diseases, 1982